Search results for "Interleukin-1 inhibitors"

showing 3 items of 3 documents

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct